Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Electrophoresis uses electrical currents to separate DNA, RNA, proteins and carbohydrates based on their charge and size. Since its discovery over 200 years ago, this technique has evolved into an ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) therapy lusvertikimab as the French biotech maps out a financially ...

A federal judge in Maine has put the brakes on a pilot program that would have enabled biopharma companies to offer rebates instead of discounts as part of the 340B program beginning Jan. 1, 2026.

Adam had started being public about his illness early on. In countless social media posts, blog posts, and TikToks, he ...